UniPharma Co., Ltd. (TPEX:6621)
Taiwan · Delayed Price · Currency is TWD 11.45
0.00 (0.00%)
Sep 8, 2026, 12:51 PM CST
UniPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 83.87 | 88.44 | 93.46 | 103.22 | 128.11 | 105.39 | |
Revenue Growth | -7.61% | -5.36% | -9.46% | -19.43% | 21.56% | -23.98% |
Cost of Revenue | 41.22 | 41.22 | 44.75 | 52.21 | 53.49 | 46.06 |
Gross Profit | 42.65 | 47.22 | 48.71 | 51.02 | 74.62 | 59.33 |
Selling, General & Admin | 66.48 | 68.52 | 62.96 | 60.49 | 69.18 | 66.5 |
Research & Development | 21.96 | 22.83 | 16.57 | 17.83 | 26.32 | 33.05 |
Operating Expenses | 88.45 | 91.35 | 79.53 | 78.32 | 95.5 | 99.55 |
Operating Income | -45.79 | -44.13 | -30.82 | -27.31 | -20.88 | -40.22 |
Interest Expense | -0.16 | -0.1 | -0.11 | -0.01 | -0.04 | -0.1 |
Interest & Investment Income | 1.96 | 2.08 | 1.95 | 1.97 | 1.26 | 1.24 |
Currency Exchange Gain (Loss) | 2.8 | -0.83 | 1.15 | -0.05 | 0.97 | -0.21 |
Other Non Operating Income (Expenses) | 1.1 | 2.44 | 3.06 | 3.59 | 0.96 | 1.28 |
EBT Excluding Unusual Items | -40.09 | -40.53 | -24.78 | -21.81 | -17.74 | -38.02 |
Gain (Loss) on Sale of Assets | -0 | -0.01 | -0.04 | - | 10.71 | - |
Asset Writedown | - | - | - | - | - | -36.43 |
Other Unusual Items | - | - | - | - | - | 0.04 |
Pretax Income | -40.1 | -40.54 | -24.82 | -21.81 | -7.03 | -74.41 |
Earnings From Continuing Operations | -40.1 | -40.54 | -24.82 | -21.81 | -7.03 | -74.41 |
Minority Interest in Earnings | - | - | - | - | 0.58 | - |
Net Income | -40.1 | -40.54 | -24.82 | -21.81 | -6.45 | -74.41 |
Net Income to Common | -40.1 | -40.54 | -24.82 | -21.81 | -6.45 | -74.41 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 36 | 36 | 36 | 36 | 35 | 35 |
Shares Outstanding (Diluted) | 36 | 36 | 36 | 36 | 35 | 35 |
Shares Change | - | - | - | 0.04% | 0.81% | - |
EPS (Basic) | -1.13 | -1.14 | -0.70 | -0.61 | -0.18 | -2.11 |
EPS (Diluted) | -1.13 | -1.14 | -0.70 | -0.61 | -0.18 | -2.11 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -34.99 | -37.98 | -15.11 | 3.92 | -32.09 | -13.54 |
Free Cash Flow Per Share | -0.98 | -1.07 | -0.43 | 0.11 | -0.90 | -0.39 |
Gross Margin | 50.86% | 53.39% | 52.12% | 49.42% | 58.25% | 56.29% |
Operating Margin | -54.60% | -49.89% | -32.98% | -26.45% | -16.30% | -38.16% |
Profit Margin | -47.80% | -45.84% | -26.56% | -21.13% | -5.03% | -70.60% |
Free Cash Flow Margin | -41.71% | -42.94% | -16.17% | 3.80% | -25.05% | -12.85% |
EBITDA | -42.62 | -40.89 | -27.49 | -24.99 | -18.8 | -34.99 |
EBITDA Margin | -50.81% | -46.24% | -29.42% | -24.21% | -14.68% | -33.20% |
D&A For EBITDA | 3.18 | 3.23 | 3.33 | 2.32 | 2.07 | 5.23 |
EBIT | -45.79 | -44.13 | -30.82 | -27.31 | -20.88 | -40.22 |
EBIT Margin | -54.60% | -49.89% | -32.98% | -26.45% | -16.30% | -38.16% |